...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cellular Physiology >Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
【24h】

Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

机译：基线嗜中性,派生中性粒细胞~量淋巴细胞比率(dNLR),血小板量至淋巴细胞比率(PLR),和结果在非小细胞肺癌(NSCLC)治疗Nivolumab或多烯紫杉醇

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Nivolumab is a novel therapeutic option in NSCLC, associated with a significant survival gain compared with Docetaxel. However, predictive biomarkers are lacking. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response to Nivolumab or Docetaxel in pre‐treated NSCLCs. Data of 62 patients receiving Nivolumab or Docetaxel were analyzed. Baseline neutrophilia and thrombocytosis were not associated with response. High dNLR was associated with no response to Nivolumab, but not with Docetaxel, whereas high PLR correlated with low treatment response in both groups. Among refractory patients, a higher incidence of thrombocytosis, neutrophilia, high PLR, and high dNLR levels were observed compared with the overall population. This is one of the first reports in this field and suggests that indicators of inflammation might be included together with other predictive biomarkers in the baseline evaluation of patients candidate for immunotherapy.
机译：Nivolumab小说在非小细胞肺癌治疗选择,关联到一个重要的生存利益相比之下,多西他赛。生物标志物是缺乏。炎症与贫穷在许多癌症的结果。评估是否有相关性一些炎症指标和响应Nivolumab或提前多烯紫杉醇治疗非小细胞肺癌。62名患者接受Nivolumab或数据多西他赛进行了分析。和血小板增多并不相关响应。Nivolumab反应,但不与多西他赛,而高PLR与低治疗反应两组。病人,血小板增多的发生率高,嗜中性、高PLR, dNLR水平高观察到与整个人口。这是第一个报告在这个领域,表明炎症指标与其他预测可能包含在一起生物标志物在基线评估的患者候选免疫疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号